WHO admits Kazakh COVID-19 vaccine for clinical trials

NUR-SULTAN, KAZAKHSTAN – The World Health Organization (WHO) has allowed Kazakhstan’s coronavirus vaccine for clinical trials, Kazakh Health Minister Alexei Tsoi said at a briefing on October 15.

The World Health Organization officially admitted the Kazakh vaccine to clinical trials to assess the safety of the vaccine’s effectiveness. On September 17, permission was obtained to conduct the first phase of clinical trials at the Scientific Center for Phthisiopulmonology,” Tsoi said.

He added that the completion of the second phase of clinical trials is planned on November 17 this year.

“The third phase will last until the end of April 2021,” the minister said.

Recall, on September 16, it became known that the second Kazakh vaccine against coronavirus was included in the list of candidate vaccines of the World Health Organization.

Both Kazakh vaccines are on the list of candidate vaccines published on the WHO website.

The second vaccine is a joint development of the International Vaccine Center of KazNAU and the National Scientific Center for Highly Dangerous Infections named after M. Aikimbaev, now it is undergoing preclinical studies.

On July 31, the World Health Organization (WHO) included the Kazakh inactivated vaccine against coronavirus QazCovid-in️ in the list of candidate vaccines approved for clinical trials.

Seven vaccine developers, led by the institute’s director, became the first volunteers to receive the vaccine to protect their safety while working with the virus. According to the test results, all have developed antibodies to the virus, the employees are healthy and continue to work within the framework of the scientific and technical program.

627 people agreed to take part in clinical trials of the QazCovid-in vaccine.

News by NewEurope

Enter your email address:

We will be happy to hear your thoughts

      Leave a reply

      IndiaClicking - Buzzing News & Stocks